Form 4: Tango Therapeutics R&D President Sells Shares

Adam Crystal, President of R&D at Tango Therapeutics, Inc., sold 54,345 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Adam Crystal, President of Research & Development at Tango Therapeutics, Inc. (TNGX), disposed of 54,345 shares of the company's common stock.
• The transaction occurred on February 25, 2026.
• The shares were sold at a weighted average price of $12.7741 per share, with individual sales prices ranging from $12.61 to $13.09.
• Following this transaction, Adam Crystal beneficially owns 132,873 shares of Tango Therapeutics common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan that was adopted on October 27, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to the insider sale of a notable number of shares, even though it was executed under a Rule 10b5-1 plan, which mitigates concerns about opportunistic timing.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information and is part of a scheduled personal financial management strategy.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived as a slight negative signal regarding management's confidence in the near-term stock price.
• A significant number of shares (54,345) were disposed of by a key executive.

Future Outlook

No forward-looking statements or guidance regarding the company's future performance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common in the biotechnology sector as executives often receive significant equity compensation. While this sale was pre-planned, it occurs in a sector known for high volatility and sensitivity to news, making insider activity closely watched by investors for sentiment indicators.

Corporate Governance

Related Party Transactions

• The sale of common stock by Adam Crystal, an officer of Tango Therapeutics, Inc., is considered a related party transaction.

Stakeholder Impact

• Shareholders may interpret the insider sale as a slight negative signal, potentially influencing their perception of the stock's near-term prospects.
• The transaction is part of a pre-planned strategy for management, indicating personal financial planning rather than a direct statement on company performance.

Key Dates

Recommendation

While the insider sale by the President of R&D is a notable event, it was executed under a pre-arranged 10b5-1 plan, which reduces the immediate concern of opportunistic selling. Without additional company-specific news or financial performance data, a 'hold' recommendation is appropriate, advising investors to monitor future developments and broader market trends for Tango Therapeutics.

Keywords

Tango Therapeutics, TNGX, Adam Crystal, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals